Alembic Pharmaceuticals Limited has notified the stock exchanges regarding the resignation of Mr. Goldee Pardesi from the position of Associate Vice President - Sales & Marketing. The resignation became effective from 4th May 2026, at the close of business hours, as per the intimation submitted to BSE Limited and National Stock Exchange of India Ltd.

The disclosure was made pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company has attached the required details as per the Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated 30th January 2026.

Resignation Details

The following table outlines the key particulars of the change in senior management personnel:

The resignation intimation was signed by Manisha Saraf, Company Secretary of alembic pharmaceuticals , on 4th May 2026. The company's registered office is located at Alembic Road, Vadodara - 390 003.

The resignation follows an email communication from Mr. Pardesi dated 3rd February 2026, wherein he formally tendered his resignation to pursue new opportunities aligned with his professional and personal goals. He expressed gratitude for the support and opportunities provided during his tenure at the company.

Alembic Pharmaceuticals witnessed a notable block trade on the National Stock Exchange (NSE), with approximately 2,01,791 shares transacted at a price of ₹769.05 per share, aggregating to a total deal value of ₹15.52 crores.

Block Trade Details

The following table summarizes the key parameters of the block trade recorded on the NSE:

Transaction Overview

Block trades are large-volume transactions typically executed by institutional investors or significant market participants, often conducted outside the regular order book to minimize market impact. The trade in Alembic Pharmaceuticals involved approximately 2,01,791 shares at ₹769.05 apiece, culminating in a cumulative deal size of ₹15.52 crores on the NSE.